Moderna awaits FDA decision on mRNA flu vaccine as biotech fund launches and pricing disputes intensify
read at STAT ↗Neutral
Moderna is awaiting the FDA's decision on its mRNA influenza vaccine, which could become the first seasonal flu shot using messenger RNA technology.
Meanwhile, venture firm TCGX announced a new $400 million fund focused on biotech companies operating in Asia, aiming to support regional development.
The article also highlights a renewed dispute over 340B drug‑rebate rules and fresh legal scrutiny of Eli Lilly's insulin pricing practices, underscoring ongoing regulatory challenges.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Is there a pharma mega-merger in the making?”
read at STAT ↗354 words · retrieved Aug 3
comments(0)
5-min edit window · permanent after that